Results

Total Results: over 10,000 records

Showing results for "choice".

  1. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cad-women-treatment_executive.pdf
    August 01, 2012 - Uncertainty exists about the choice between PCI and CABG for patients with moderate CAD burden; namely
  2. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cad-women-treatment_executive.pdf
    August 01, 2012 - Uncertainty exists about the choice between PCI and CABG for patients with moderate CAD burden; namely
  3. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-apps-a-e-surveillance-report-2.pdf
    January 01, 2022 - CBDa THC Synthetic THC THC to CBD Ratio Unclear High High Source Any cannabis product (patient’s choice … 1,514 4-year followup: 1,217 Groups unclear 4 years Unclear THC concentration; patient- driven choice … authorization for medical cannabis in Canada (5,373) 20 months Unknown THC concentration; patient- driven choice … month use of marijuana (65) C: No use (313) 52 weeks Unknown THC concentration; patient- driven choice
  4. effectivehealthcare.ahrq.gov/sites/default/files/product/pdf/cer-250-cannabis-apps-a-e-surveillance-report-2.pdf
    January 01, 2022 - CBDa THC Synthetic THC THC to CBD Ratio Unclear High High Source Any cannabis product (patient’s choice … 1,514 4-year followup: 1,217 Groups unclear 4 years Unclear THC concentration; patient- driven choice … authorization for medical cannabis in Canada (5,373) 20 months Unknown THC concentration; patient- driven choice … month use of marijuana (65) C: No use (313) 52 weeks Unknown THC concentration; patient- driven choice
  5. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-apps-a-e-surveillance-report-2-final.pdf
    February 01, 2022 - CBDa THC Synthetic THC THC to CBD Ratio Unclear High High Source Any cannabis product (patient’s choice … 1,514 4-year followup: 1,217 Groups unclear 4 years Unclear THC concentration; patient-driven choice … authorization for medical cannabis in Canada (5,373) 20 months Unknown THC concentration; patient-driven choice … month use of marijuana (65) C: No use (313) 52 weeks Unknown THC concentration; patient-driven choice
  6. effectivehealthcare.ahrq.gov/sites/default/files/product/pdf/cer-250-cannabis-apps-a-e-surveillance-report-2-final.pdf
    March 01, 2022 - CBDa THC Synthetic THC THC to CBD Ratio Unclear High High Source Any cannabis product (patient’s choice … 1,514 4-year followup: 1,217 Groups unclear 4 years Unclear THC concentration; patient-driven choice … authorization for medical cannabis in Canada (5,373) 20 months Unknown THC concentration; patient-driven choice … month use of marijuana (65) C: No use (313) 52 weeks Unknown THC concentration; patient-driven choice
  7. effectivehealthcare.ahrq.gov/sites/default/files/product/pdf/cer-250-cannabis-surveillance-report-3.pdf
    May 01, 2022 - CBDa THC Synthetic THC THC to CBD Ratio Unclear High High Source Any cannabis product (patient’s choice … 1,514 4-year followup: 1,217 Groups unclear 4 years Unclear THC concentration; patient- driven choice … authorization for medical cannabis in Canada (5,373) 20 months Unknown THC concentration; patient- driven choice … month use of marijuana (65) C: No use (313) 52 weeks Unknown THC concentration; patient- driven choice
  8. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-apps-a-e-surveillance-report-2-final_0.pdf
    March 01, 2022 - CBDa THC Synthetic THC THC to CBD Ratio Unclear High High Source Any cannabis product (patient’s choice … 1,514 4-year followup: 1,217 Groups unclear 4 years Unclear THC concentration; patient-driven choice … authorization for medical cannabis in Canada (5,373) 20 months Unknown THC concentration; patient-driven choice … month use of marijuana (65) C: No use (313) 52 weeks Unknown THC concentration; patient-driven choice
  9. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-surveillance-report-3.pdf
    May 01, 2022 - CBDa THC Synthetic THC THC to CBD Ratio Unclear High High Source Any cannabis product (patient’s choice … 1,514 4-year followup: 1,217 Groups unclear 4 years Unclear THC concentration; patient- driven choice … authorization for medical cannabis in Canada (5,373) 20 months Unknown THC concentration; patient- driven choice … month use of marijuana (65) C: No use (313) 52 weeks Unknown THC concentration; patient- driven choice
  10. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-surveillance-report-3_0.pdf
    May 01, 2022 - CBDa THC Synthetic THC THC to CBD Ratio Unclear High High Source Any cannabis product (patient’s choice … 1,514 4-year followup: 1,217 Groups unclear 4 years Unclear THC concentration; patient- driven choice … authorization for medical cannabis in Canada (5,373) 20 months Unknown THC concentration; patient- driven choice … month use of marijuana (65) C: No use (313) 52 weeks Unknown THC concentration; patient- driven choice
  11. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-apps-a-e-surveillance-report-2-final_0_0.pdf
    March 01, 2022 - CBDa THC Synthetic THC THC to CBD Ratio Unclear High High Source Any cannabis product (patient’s choice … 1,514 4-year followup: 1,217 Groups unclear 4 years Unclear THC concentration; patient-driven choice … authorization for medical cannabis in Canada (5,373) 20 months Unknown THC concentration; patient-driven choice … month use of marijuana (65) C: No use (313) 52 weeks Unknown THC concentration; patient-driven choice
  12. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-surveillance-report-3_0.pdf
    May 01, 2022 - CBDa THC Synthetic THC THC to CBD Ratio Unclear High High Source Any cannabis product (patient’s choice … 1,514 4-year followup: 1,217 Groups unclear 4 years Unclear THC concentration; patient- driven choice … authorization for medical cannabis in Canada (5,373) 20 months Unknown THC concentration; patient- driven choice … month use of marijuana (65) C: No use (313) 52 weeks Unknown THC concentration; patient- driven choice
  13. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-apps-a-e-surveillance-report-2-final_0_0.pdf
    March 01, 2022 - CBDa THC Synthetic THC THC to CBD Ratio Unclear High High Source Any cannabis product (patient’s choice … 1,514 4-year followup: 1,217 Groups unclear 4 years Unclear THC concentration; patient-driven choice … authorization for medical cannabis in Canada (5,373) 20 months Unknown THC concentration; patient-driven choice … month use of marijuana (65) C: No use (313) 52 weeks Unknown THC concentration; patient-driven choice
  14. effectivehealthcare.ahrq.gov/sites/default/files/related_files/obesity-child_executive.pdf
    March 31, 2010 - 1 Comparative Effectiveness Review Number 115 Childhood Obesity Prevention Programs: Comparative Effectiveness Review and Meta-Analysis Executive Summary Background The epidemic of childhood obesity is threatening America’s children.1-3 Overweight children and adolescents are at greater risk for health pr…
  15. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/obesity-child_executive.pdf
    March 31, 2010 - 1 Comparative Effectiveness Review Number 115 Childhood Obesity Prevention Programs: Comparative Effectiveness Review and Meta-Analysis Executive Summary Background The epidemic of childhood obesity is threatening America’s children.1-3 Overweight children and adolescents are at greater risk for health pr…
  16. digital.ahrq.gov/sites/default/files/docs/page/CongressionalBudgetOffice.pdf
    January 01, 2009 - The EHR might also have a feature that could suggest a drug that might be a better choice, given
  17. cds.ahrq.gov/sites/default/files/cds/artifact/1071/Implementation%20Guide_Healthful%20Diet%20and%20Physical%20Activity_Final_0.pdf
    September 01, 2021 - expressions like this artifact can use the tool to develop new CDS logic in the clinical domain of their choice … and their primary healthcare clinician to determine together the most appropriate treatment or care choice
  18. cds.ahrq.gov/sites/default/files/cds/artifact/1061/IG%20Abnormal%20Blood%20Glucose%20Type%202%20DM%20Screening.pdf
    September 01, 2021 - expressions like this artifact can use the tool to develop new CDS logic in the clinical domain of their choice … and their primary healthcare clinician to determine together the most appropriate treatment or care choice
  19. www.ahrq.gov/sites/default/files/publications/files/cuspsuccess.pdf
    October 01, 2012 - insertion and maintenance 9 bundles, daily rounding, educating new nurses, bimonthly IV classes, choice … Being only 30 minutes from Nashville and its choice of hospitals, he was acutely aware that “we have
  20. cds.ahrq.gov/sites/default/files/cds/artifact/1061/508_2022_CDS_Connect_IG_T2DM_Part_One_Screening_final.pdf
    January 01, 2022 - developing CDS logic expressions can use the tool to develop new CDS logic in the clinical domain of their choice … and their primary healthcare clinician to determine together the most appropriate treatment or care choice